Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

Drug company Eli Lilly announced it will cut the price of its insulin by 70 percent. How much will the drug cost and what does this mean for people with diabetes? Here's everything you need to ...

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions of 70% for its most commonly prescribed insulins, as well as expansion of its Insulin Value Program, capping ...

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Lilly's arch-rival in the diabetes category Novo Nordisk is working on its own glucose-sending insulin platform, acquired via its $800 million acquisition of UK biotech Ziylo in 2018.

Drug giant Eli Lilly has announced a $35 (£30) cap on the monthly costs patients face for insulin in the US, responding to outcry over the soaring cost of the diabetes medication. More than eight ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Today, anyone using Lilly insulin and enrolled in one of its programs – regardless of their insurance status – is eligible to purchase their monthly prescription for $35. Through the Lilly ...

The outcomes speak for themselves. "Lilly has been working for years to reduce insulin out-of-pocket costs for people with diabetes, against the headwinds of those — like the parties filing ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug manufacturers for allegedly colluding to inflate the cost of insulin.

Six years ago, the average monthly out-of-pocket cost for insulin made by Eli Lilly was $38.64. It’s now $17.16, a 56% drop. In other words, insulin manufacturers have been dropping their prices ...